Not All Placebos Are Equal in Knee Osteoarthritis

Share this content:
Not All Placebos Are Equal in Knee Osteoarthritis
Not All Placebos Are Equal in Knee Osteoarthritis

TUESDAY, July 28, 2015 (HealthDay News) -- Not all placebos are equally effective for knee osteoarthritis and some can trigger clinically relevant responses, according to a review published online July 28 in the Annals of Internal Medicine.

Raveendhara R. Bannuru, M.D., Ph.D., from Tufts University in Boston, and colleagues examined the effects of alternative placebo types on pain outcomes in knee osteoarthritis. Data were included from 149 randomized trials of adults with knee osteoarthritis that reported pain outcomes. The trials compared widely used pharmaceuticals against four placebos: oral, intra-articular, topical, and oral plus topical.

The researchers found that based on a network meta-analysis with four separate placebo nodes (differential model), intra-articular placebo and topical placebo had significantly greater effect sizes than oral placebo (effect sizes, 0.29 and 0.20, respectively). Compared with a network model that considered all placebos equivalent, the differential model showed marked differences in the relative efficacies and hierarchy of the active treatments. For pain reduction, intra-articular and topical therapies were superior to oral treatments in the model accounting for differential effects. Oral nonsteroidal anti-inflammatory drugs were superior when these effects were ignored.

"Differential placebo effects can substantially alter estimates of the relative efficacies of active treatments, an important consideration for the design of clinical trials and interpretation of the results," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »